MCIG continues to develop and strengthen its cannabis supply venture, Cannabiz Supply. The business has grown in various areas -- selling state mandated and custom packaging, office, dispensary supplies, and vape products. The company has gained multiple accounts with distribution to every dispensary, major grower, and production facility in Nevada.
In April, MCIG launched 420cloud.com, a mobile application available on both Android and Apple devices. MCIG anticipates revenue in FY2018 from advertising, microtransactions, payment processing, and retail sales through the new platform.
Since its acquisition of VitaCig in June 2016, MCIG revenue has grown to $1 million annually. They expect this to double this year.
Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017
TEL AVIV, Israel, June 2, 2017 Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today Provides Shareholders Update for June 2017:
Cannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled.
Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis. For the understanding of the palliative aspects, dosages and side effects, we perform a clinical study on advanced cancer patients suffering from CACS. The results up-to-date have revealed the optimal dosages for an oral treatment of naïve patients avoiding side effects.
In the understanding of the anti-cancer properties we are currently analyzing a large body of data obtained from our high throughput screening research. Furthermore, we are gaining new data from our study on circulating tumor cells (CTC), currently focusing on the cannabinoids - CBD and CBDA. We are also engaged in creating software for big data analysis and its presentation to doctors.
The recent raising of $ 3 million enables us to create the platform for personalized treatment with cannabis that correlates to the genetics and biology of the patient and the cancer. To do so the company plans to market the diagnostic tests to cancer patients treated with cannabis, expand collaborations with biotech companies and harness new technologies that examine anti-tumor properties in our R&D lab in Israel.
217